Company intelligence / Profile preview
ChemDiv
San Diego, California, United Stateschemdiv.com ↗
- Ownership
- Private
- Employees
- ~500
- Development stage
- Commercial
01
Overview
ChemDiv has delivered hundreds of leads and drug candidates across multiple therapeutic areas. Its most advanced disclosed program is AVN‑322 for Alzheimer disease in Phase 2. Other programs are in preclinical stages targeting oncology and metabolic diseases.
- Therapeutic areas
- OncologyNeurologyHematology
- Modalities
- Small moleculeChemical drugs (including inhibitors, repurposed drugs, and building blocks)
- Industry
- Contract Research Organization
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Numerous pharma, biotech & academic partners globally; specific names not listed but over “2500 customers worldwide”
Beyond the preview
Go deeper on ChemDiv.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChemDiv.